Lineage Cell Therapeutics recorded $2.8 million in revenue, up from $1.4 million in the prior-year quarter, primarily from collaborations. However, the company incurred a $30.5 million net loss due to a $14.8 million impairment on an intangible asset and a $12.7 million fair value adjustment on warrant liabilities.

Lineage Cell Therapeutics posted a reduced net loss in Q1 2025 as operating expenses slightly declined and other income rose due to changes in warrant liabilities. The company continued progressing its clinical programs including OpRegen and OPC1.

Lineage Cell Therapeutics' Q4 2024 revenue increased to $2.9 million, up from $2.1 million in Q4 2023, primarily due to higher collaboration revenue. The company reported a net loss of $3.3 million, improving from a $4.8 million loss in the prior year. Operating expenses decreased slightly to $7.8 million, driven by lower R&D costs. Cash and cash equivalents stood at $45.8 million at quarter-end, providing operational runway into Q1 2027.

Lineage Cell Therapeutics reported a net loss attributable to Lineage of $3.0 million, or $0.02 per share, for the three months ended September 30, 2024. Total revenues for the quarter were $3.8 million, an increase of approximately $2.5 million compared to the same period in 2023. Cash, cash equivalents, and marketable securities totaled $32.7 million as of September 30, 2024.

Lineage Cell Therapeutics reported a net loss of $5.8 million, or $0.03 per share, for the three months ended June 30, 2024. Total revenues for the quarter were $1.4 million. Cash, cash equivalents, and marketable securities totaled $38.5 million as of June 30, 2024, expected to support planned operations into Q4 2025.

Lineage Cell Therapeutics reported a decrease in revenue compared to the same period last year, primarily due to lower collaboration and licensing revenue. Operating expenses also decreased, driven by reductions in R&D spending across multiple programs. The company's cash position is expected to support operations into Q3 2025.

Lineage Cell Therapeutics reported Q4 2023 revenues of $2.1 million and a net loss of $4.8 million, or $0.03 per share. The company's cash, cash equivalents, and marketable securities totaled $35.5 million as of December 31, 2023, expected to support operations into Q3 2025.

Lineage Cell Therapeutics reported a net loss of $7.1 million, or $0.04 per share, for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $41.3 million as of September 30, 2023, expected to support operations into Q1 2025. Total revenues for the quarter were $1.2 million.

Lineage Cell Therapeutics reported a net loss of $5.2 million, or $0.03 per share, for the second quarter ended June 30, 2023. Total revenues were $3.2 million, and total operating expenses were $8.1 million. Cash, cash equivalents, and marketable securities totaled $45.9 million as of June 30, 2023.

Lineage Cell Therapeutics reported a decrease in revenue driven by less collaboration and licensing revenue recognized from the Roche Agreement, while operating expenses also decreased due to lower litigation and legal expenses.

Lineage Cell Therapeutics reported a net loss attributable to Lineage for the three months ended December 31, 2022 was $6.4 million, or $0.03 per share (basic and diluted). Total revenues for the three months ended December 31, 2022 were approximately $1.9 million.

Lineage Cell Therapeutics reported a net loss attributable to Lineage for the three months ended September 30, 2022, was $6.1 million, or $0.04 per share (basic and diluted), compared to a net loss attributable to Lineage of $7.8 million, or $0.05 per share (basic and diluted), for the same period in 2021. Total revenues for the three months ended September 30, 2022 were approximately $3.0 million, a net increase of $0.7 million as compared to $2.3 million for the same period in 2021.

Lineage Cell Therapeutics reported a revenue of $4.6 million for the second quarter of 2022, primarily from licensing fees, royalties, collaboration revenues, and research grants. The net loss attributable to Lineage was $6.8 million, or $0.04 per share.

Lineage Cell Therapeutics reported first quarter 2022 financial results, including revenues of $5.2 million, primarily from licensing fees related to the Roche collaboration, and a net loss of $7.1 million, or $0.04 per share.

Lineage Cell Therapeutics reported total revenues of $1.2 million for the fourth quarter ended December 31, 2021, an increase of $0.8 million compared to the same period in 2020. The net loss attributable to Lineage for the three months ended December 31, 2021 was ($29.0) million, or ($0.17) per share (basic and diluted). Cash and cash equivalents totaled $55.7 million as of December 31, 2021.

Lineage Cell Therapeutics reported a net loss of $7.8 million, or $0.05 per share, for the third quarter of 2021. Total revenues were $2.3 million, an increase of $1.7 million compared to the same period in 2020. Cash, cash equivalents, and marketable securities totaled $65.1 million as of September 30, 2021.

Lineage Cell Therapeutics reported financial and operating results for the second quarter 2021, with revenue of $0.5 million and a net loss attributable to Lineage of $4.8 million, or $0.03 per share.

Lineage Cell Therapeutics reported significant operational progress with its three clinical programs, including positive clinical results with OpRegen and strategic collaborations for OPC1 and VAC programs. The company is well funded to reach additional milestones due to capital raised during the quarter.

Lineage Cell Therapeutics reported a net income of $2.0 million for the fourth quarter of 2020, compared to a net loss of $4.5 million for the same period in 2019. Total revenues for the quarter were $0.4 million, a decrease of $0.8 million compared to the same period in 2019. Cash, cash equivalents, and marketable securities totaled $41.6 million as of December 31, 2020.

Lineage Cell Therapeutics reported third quarter 2020 financial results, with a net loss of $7.8 million, or $0.05 per share, and total revenues of $0.6 million, consistent with the same period in 2019. The company's cash, cash equivalents, and marketable securities totaled $38.0 million as of September 30, 2020, including $24.6 million from Juvenescence.

Lineage Cell Therapeutics reported positive milestones across its cell therapy pipeline, including retinal tissue restoration in a dry AMD patient. The company is advancing its dendritic cell vaccine program and making manufacturing improvements for its OPC1 program.

Lineage Cell Therapeutics reported first quarter 2020 financial results, including revenues of $0.5 million and a net loss of $8.4 million, or $0.06 per share. The company's cash, cash equivalents, and marketable securities totaled $25.8 million as of March 31, 2020.

Lineage Cell Therapeutics reported Q4 2019 revenues of $1.2 million, an increase of $0.4 million compared to 2018. The net loss attributable to Lineage for the quarter was $4.5 million, or $0.03 per share, compared to a net loss of $45.0 million, or $0.35 per share, for the same period in 2018.